🚀 VC round data is live in beta, check it out!
TG Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for TG Therapeutics and similar public comparables like SK Biopharmaceuticals, Xenon Pharmaceuticals, Gan and Lee, Beijing Tongrentang and more.
TG Therapeutics Overview
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Founded
1993
HQ
Employees
338
Website
Sectors
Financials (LTM)
EV
$6B
TG Therapeutics Financials
TG Therapeutics reported last 12-month revenue of $700M and EBITDA of $162M.
In the same LTM period, TG Therapeutics generated $587M in gross profit, $162M in EBITDA, and $381M in net income.
Revenue (LTM)
TG Therapeutics P&L
In the most recent fiscal year, TG Therapeutics reported revenue of $616M and EBITDA of $134M.
TG Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $700M | XXX | $616M | XXX | XXX | XXX |
| Gross Profit | $587M | XXX | $516M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | $162M | XXX | $134M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $381M | XXX | $447M | XXX | XXX | XXX |
| Net Margin | 54% | XXX | 73% | XXX | XXX | XXX |
| Net Debt | — | — | $166M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TG Therapeutics Stock Performance
TG Therapeutics has current market cap of $6B, and enterprise value of $6B.
Market Cap Evolution
TG Therapeutics' stock price is $35.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $6B | 3.0% | XXX | XXX | XXX | $2.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTG Therapeutics Valuation Multiples
TG Therapeutics trades at 8.2x EV/Revenue multiple, and 35.5x EV/EBITDA.
EV / Revenue (LTM)
TG Therapeutics Financial Valuation Multiples
As of April 18, 2026, TG Therapeutics has market cap of $6B and EV of $6B.
Equity research analysts estimate TG Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TG Therapeutics has a P/E ratio of 14.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 8.2x | XXX | 9.3x | XXX | XXX | XXX |
| EV/EBITDA | 35.5x | XXX | 42.8x | XXX | XXX | XXX |
| EV/EBIT | 34.6x | XXX | 46.7x | XXX | XXX | XXX |
| EV/Gross Profit | 9.8x | XXX | 11.2x | XXX | XXX | XXX |
| P/E | 14.8x | XXX | 12.6x | XXX | XXX | XXX |
| EV/FCF | 17.0x | XXX | 15.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TG Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TG Therapeutics Margins & Growth Rates
TG Therapeutics' revenue in the last 12 month grew by 39%.
TG Therapeutics' revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $1.2M for the same period.
TG Therapeutics' rule of 40 is 74% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TG Therapeutics' rule of X is 143% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
TG Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 39% | XXX | 46% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 84% | XXX | 89% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 74% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 143% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.2M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 38% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 24% | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TG Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TG Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SK Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Xenon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Gan and Lee | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Tongrentang | XXX | XXX | XXX | XXX | XXX | XXX |
| CRISPR Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TG Therapeutics M&A Activity
TG Therapeutics acquired XXX companies to date.
Last acquisition by TG Therapeutics was on XXXXXXXX, XXXXX. TG Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TG Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTG Therapeutics Investment Activity
TG Therapeutics invested in XXX companies to date.
TG Therapeutics made its latest investment on XXXXXXXX, XXXXX. TG Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TG Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TG Therapeutics
| When was TG Therapeutics founded? | TG Therapeutics was founded in 1993. |
| Where is TG Therapeutics headquartered? | TG Therapeutics is headquartered in United States. |
| How many employees does TG Therapeutics have? | As of today, TG Therapeutics has over 338 employees. |
| Who is the CEO of TG Therapeutics? | TG Therapeutics' CEO is Michael S. Weiss. |
| Is TG Therapeutics publicly listed? | Yes, TG Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of TG Therapeutics? | TG Therapeutics trades under TGTX ticker. |
| When did TG Therapeutics go public? | TG Therapeutics went public in 1995. |
| Who are competitors of TG Therapeutics? | TG Therapeutics main competitors are SK Biopharmaceuticals, Xenon Pharmaceuticals, Gan and Lee, Beijing Tongrentang. |
| What is the current market cap of TG Therapeutics? | TG Therapeutics' current market cap is $6B. |
| What is the current revenue of TG Therapeutics? | TG Therapeutics' last 12 months revenue is $700M. |
| What is the current revenue growth of TG Therapeutics? | TG Therapeutics revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of TG Therapeutics? | Current revenue multiple of TG Therapeutics is 8.2x. |
| Is TG Therapeutics profitable? | Yes, TG Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TG Therapeutics? | TG Therapeutics' last 12 months EBITDA is $162M. |
| What is TG Therapeutics' EBITDA margin? | TG Therapeutics' last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of TG Therapeutics? | Current EBITDA multiple of TG Therapeutics is 35.5x. |
| What is the current FCF of TG Therapeutics? | TG Therapeutics' last 12 months FCF is $338M. |
| What is TG Therapeutics' FCF margin? | TG Therapeutics' last 12 months FCF margin is 48%. |
| What is the current EV/FCF multiple of TG Therapeutics? | Current FCF multiple of TG Therapeutics is 17.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.